FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Feb 26, 2026
Rocket Pharmaceuticals, Inc. (RCKT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $223.1 million. Free cash flow was -$190.5 million. As of Jun 30, 2026 it held $283.7 million in cash and investments and $24.8 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-17.25M
+93.3% vs year-ago TTM
Operating cash flow (TTM)
$-170.27M
+16.5% vs year-ago TTM
Free cash flow (TTM)
$-170.39M
+17.3% vs year-ago TTM
EPS (TTM)
$-0.15
+93.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
108.57M
+1.8% vs prior year
Net cash
$258.95M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RCKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1281895
- Former names
- INOTEK PHARMACEUTICALS CORP (until Dec 22, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M |
| Diluted EPS | -$2.01 | -$2.73 | -$2.92 | -$3.26 | -$2.67 |
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
| Stockholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M |
| Cash and investments | $188.9M | $372.3M | $407.5M | $399.7M | $388.7M |
| Total debt | $24.9M | $25.5M | $25.0M | $22.9M | $22.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 3, 2026 | Aug 3, 2026 |
All 968 Rocket Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.